[{"address1": "7800 Susquehanna St.", "address2": "Suite 505", "city": "Pittsburgh", "state": "PA", "zip": "15208", "country": "United States", "phone": "412 894 1853", "website": "https://www.lipella.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan  Kaufman M.B.A., Ph.D.", "age": 56, "title": "Co-Founder, Chairman, CEO, President, Secretary & Treasurer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 204133, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael B. Chancellor M.D.", "age": 64, "title": "Co-Founder, Chief Medical Officer & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 195833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michele  Gruber", "title": "Director of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Katie  Johnston", "title": "Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.02, "open": 0.875, "dayLow": 0.7706, "dayHigh": 0.875, "regularMarketPreviousClose": 1.02, "regularMarketOpen": 0.875, "regularMarketDayLow": 0.7706, "regularMarketDayHigh": 0.875, "volume": 1180684, "regularMarketVolume": 1180684, "averageVolume": 22795, "averageVolume10days": 71640, "averageDailyVolume10Day": 71640, "bid": 0.81, "ask": 0.825, "bidSize": 3200, "askSize": 800, "marketCap": 5048774, "fiftyTwoWeekLow": 0.7706, "fiftyTwoWeekHigh": 2.93, "priceToSalesTrailing12Months": 11.229055, "fiftyDayAverage": 1.00458, "twoHundredDayAverage": 1.5279, "currency": "USD", "enterpriseValue": 3280391, "floatShares": 3800083, "sharesOutstanding": 6250030, "sharesShort": 25644, "sharesShortPriorMonth": 9200, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0042, "heldPercentInsiders": 0.36235002, "heldPercentInstitutions": 0.0592, "shortRatio": 1.98, "shortPercentOfFloat": 0.0055, "impliedSharesOutstanding": 6371390, "bookValue": 0.519, "priceToBook": 1.5564548, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -4618965, "trailingEps": -0.73, "enterpriseToRevenue": 7.296, "enterpriseToEbitda": -0.691, "52WeekChange": -0.47979796, "SandP52WeekChange": 0.28712332, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "LIPO", "underlyingSymbol": "LIPO", "shortName": "Lipella Pharmaceuticals Inc.", "longName": "Lipella Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1671460200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d39a1b66-6fea-3b6c-8773-cda09b9e9d93", "messageBoardId": "finmb_35907207", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.8078, "recommendationKey": "none", "totalCash": 3293738, "totalCashPerShare": 0.527, "ebitda": -4744268, "totalDebt": 136594, "quickRatio": 8.631, "currentRatio": 8.899, "totalRevenue": 449617, "debtToEquity": 4.344, "revenuePerShare": 0.075, "returnOnAssets": -0.62268, "returnOnEquity": -1.1813099, "freeCashflow": -1516392, "operatingCashflow": -3150172, "revenueGrowth": -0.2, "operatingMargins": -6.0375896, "financialCurrency": "USD", "trailingPegRatio": null}]